176 related articles for article (PubMed ID: 10555128)
1. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma.
Mani S; Sciortino D; Samuels B; Arrietta R; Schilsky RL; Vokes EE; Benner S
Invest New Drugs; 1999; 17(1):97-101. PubMed ID: 10555128
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma.
Mani S; Schiano T; Garcia JC; Ansari RH; Samuels B; Sciortino DF; Tembe S; Shulman KL; Baker A; Benner SE; Vokes EE
Invest New Drugs; 1998-1999; 16(3):279-83. PubMed ID: 10360610
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
Mani S; Kugler JW; Sciortino DF; Garcia JC; Ansari RH; Humerickhouse R; Michelassi F; Posner MC; Shulman KL; Schilsky RL; List M; Vokes EE; Benner S
Ann Oncol; 1998 Sep; 9(9):1035-7. PubMed ID: 9818081
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.
Pazdur R; Lassere Y; Diaz-Canton E; Bready B; Ho DH
Invest New Drugs; 1997; 15(2):123-8. PubMed ID: 9220291
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
Pazdur R; Lassere Y; Diaz-Canton E; Ho DH
Cancer Invest; 1998; 16(3):145-51. PubMed ID: 9541627
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma.
Kim YH; Shin SW; Kim BS; Park YT; Kim JG; Kim JS
Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):119-23. PubMed ID: 9348583
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
[TBL] [Abstract][Full Text] [Related]
10. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
Furuse J; Okusaka T; Funakoshi A; Yamao K; Nagase M; Ishii H; Nakachi K; Ueno H; Ikeda M; Morizane C; Horikawa Y; Mizuno N
Jpn J Clin Oncol; 2006 Sep; 36(9):552-6. PubMed ID: 16887837
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.
Childs HA; Spencer SA; Raben D; Bonner JA; Newsome J; Robert F
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):939-44. PubMed ID: 10863063
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of UFT plus leucovorin in colorectal cancer.
Pazdur R
Oncology; 1997; 54 Suppl 1():19-23. PubMed ID: 8978580
[TBL] [Abstract][Full Text] [Related]
14. Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group.
Feliu J; González Barón M; Espinosa E; García Girón C; de la Gándara I; Espinosa J; Colmenarejo A; Jalón JI; Fernández Y; de Castro J
Cancer; 1997 May; 79(10):1884-9. PubMed ID: 9149013
[TBL] [Abstract][Full Text] [Related]
15. Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study).
Nishina T; Moriwaki T; Shimada M; Higashijima J; Sakai Y; Masuishi T; Ozeki M; Amagai K; Negoro Y; Indo S; Denda T; Sato M; Yamamoto Y; Nakajima G; Mizuta M; Takahashi I; Hiroshima Y; Ishida H; Maeba T; Hyodo I
Clin Colorectal Cancer; 2016 Sep; 15(3):236-42. PubMed ID: 26778644
[TBL] [Abstract][Full Text] [Related]
16. UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience.
González Barón M; Feliu J; Garcia Girón C; Espinosa J; Martinez B; Blanco E; Crespo MC; Ordóñez A; Espinosa E; de Castro J; Juárez F; Colmenarejo A
Oncology; 1997; 54 Suppl 1():24-9. PubMed ID: 8978581
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study.
González-Barón M; Feliu J; de la Gándara I; Espinosa E; Colmenarejo A; Martínez-Martínez B; Blanco E; García-Girón C; Juárez F; Garrido P
Eur J Cancer; 1995 Dec; 31A(13-14):2215-9. PubMed ID: 8652245
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin, cisplatin, oral UFT, and calcium folinate in advanced gastric carcinoma.
Kim YH; Kim BS; Seo JH; Choi CW; Kim JS; Chun HJ; Hyun JH; Kim JS
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):64-8. PubMed ID: 10442365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
